Trial Profile
A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cimlanod (Primary)
- Indications Decompensated heart failure
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Sponsors Cardioxyl Pharmaceuticals
- 05 Jul 2017 Results published in the European Journal of Heart Failure.
- 27 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.